Navigation Links
Genaera Corporation Announces First Quarter Financial Results
Date:5/9/2008

ot obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

GENAERA CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

Three Months Ended

March 31,

2008 2007

Revenues $ 1,309 $ 207

Costs and expenses:

Resea
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genaera Corporation Announces 2007 Financial Results
2. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera to Present at Biotech 2007 and BIO InvestorForum
5. Genaera Elects New Board Member and Announces Executive Appointments
6. EUSA Pharma Completes Acquisition Of Cytogen Corporation
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008
9. Mac-Gray Corporation Announces First-Quarter 2008 Financial Results
10. MannKind Corporation Reports First Quarter Financial Results
11. Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... 10 December 2009 -- Researchers have discovered a new explanation ... The more excess copies of a certain gene, the more ... X-chromosome; and it is suspected that it is the amount ... results are being published in the American Journal of ... the group of Guy Froyen connected to VIB, a life ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment and dosing ... Center of the first patient in the ACE ( ... fficacy) Phase 2 pivotal trial in patients with relapsed ... a novel, orally available, potent and highly selective small ... kinase-3 (FLT3) inhibitor. The ACE study is designed ...
(Date:12/11/2009)... Dec. 11 Marrone Bio Innovations (MBI) ... management team. Mr. Chris Hildreth joined MBI as ... responsible for expanding all commercial aspects of the ... Dr. Kin Sing (Ray) Lam joined MBI as ... company,s development efforts in scaling its broad pipeline ...
(Date:12/11/2009)... Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, ... announced the appointment of Dr. Alan Warrander to ... and Business Development. ,, "Dr. Warrander will be ... strategy for REOLYSIN(R)," said Dr. Brad Thompson, President ... on the design of a Phase 3 trial ...
Breaking Biology Technology:Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
... Oct. 22 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, ... Conference Call, ... Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , How: ... web at the ...
... Oct. 22 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... and commercializing novel anti-infective products, today,announced that ... to lead its field force hiring effort ... tablets, 775mg) launch. The,launch is targeted for ...
... Calif., Oct. 22 Genoptix, Inc.,(Nasdaq: GXDX ... Company,s participation at the BIOCOM Investor Conference 2008,scheduled ... La Jolla, CA on October,26-28, 2008., Dr. ... present at the,conference on Monday, October 27, beginning ...
Other Biology Technology:Webcast Alert: Transgenomic Inc. Announces Third Quarter 2008 Earnings Release Conference Call Webcast 2MiddleBrook Hires TalenTactics to Recruit National Field Force 2MiddleBrook Hires TalenTactics to Recruit National Field Force 3Genoptix Announces Participation at the BIOCOM Investor Conference 2008 2
(Date:12/14/2009)... Rice University and Baylor College of Medicine (BCM) have ... real time with MRI as it homes in on ... kills them with heat. The all-in-one particle is one ... "theranostics" that develops technologies physicians can use to diagnose ... research is available online in the journal Advanced ...
(Date:12/14/2009)... study to date of the proteins in a species ... clues to how similar regeneration could be induced in ... at Indiana University-Purdue University Indianapolis and colleagues investigated over ... a type of salamander that has the unique natural ... with the hope that this knowledge will contribute to ...
(Date:12/14/2009)... Dec. 14 MODA Technology Partners, a ... utility and product testing for the Pharmaceutical industry, ... the company,s third generation mobile data acquisition platform. ... to further automate their regulated manufacturing processes. ... ,, Fully-Configurable Test Methods: Each ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2IUPUI researchers tackle protein mechanisms behind limb regeneration 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2Kidney Injury While Hospitalized May Lead to Future Dialysis 57273 1Kidney Injury While Hospitalized May Lead to Future Dialysis 57273 2Diabetes Medications Dont Lower Inflammation 57271 1Diabetes Medications Dont Lower Inflammation 57271 2Diabetes Medications Dont Lower Inflammation 57271 3Blacks Fare Worse After Cardiac Arrest 57269 1Blacks Fare Worse After Cardiac Arrest 57269 2Blacks Fare Worse After Cardiac Arrest 57269 3
... The first comprehensive reconstruction of an extreme warm period ... in carbon dioxide (CO 2 ) levels as well ... from equatorial regions, and greenhouse gases on Earth,s temperature. ... predictions of future climate and improved understanding of today,s ...
... the challenge of global food security featuring prominently in ... such that the term "food security" has now become ... is launching the scientific journal Food Security: The ... to Food with the first issue appearing in ...
... Despite broad "dolphin safe" practices, fishing activities have continued ... Ocean dolphin population, a new report led by a ... Diego has concluded. , Populations of dolphins in the ... successful regulations and agreements were enacted to reduce dolphin ...
Other Biology News:Getting warmer? Prehistoric climate can help forecast future changes 2Springer launches Food Security 2Dolphin population stunted by fishing activities, Scripps/NOAA study finds 2Dolphin population stunted by fishing activities, Scripps/NOAA study finds 3
... Rabbit polyclonal to Endothelin B ... Type B Receptor-Like Protein 2 (ETBR-LP-2) ... ESTs have been isolated from human ... Immunogen: Synthetic peptide (unfortunately, the ...
Mouse monoclonal [164-12-2] to Ampicillin ( Abpromise for all tested applications)....
... product contains 5 ml Dynabeads Epoxy (4.5 ... ether (epoxy) reactive groups. Ideal for coupling ... absorbed hydrophobically on initial coupling with covalent ... and sulphydryll groups (SH)) occurring within ...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
Biology Products: